BeOne resolves patent dispute with Pharmacyclics

BeOne Medicines Ltd. announced that Pharmacyclics LLC has decided not to appeal the Final Written Decision from the U.S. Patent and Trademark Office. This decision invalidated all claims of Pharmacyclics' U.S. Patent No. 11,672,803 (the ‘803 patent), which BeOne had challenged in a post-grant review proceeding.

On September 30, 2025 (U.S. Time), BeOne and Pharmacyclics filed a joint stipulation to voluntarily dismiss their related district court litigation with prejudice. This action fully resolves the patent dispute, as confirmed by BeOne’s announcement on October 2, 2025.

The company's board of directors includes John V. Oyler as chairman and executive director, alongside Dr. Xiaodong Wang as a non-executive director, and a diverse group of independent non-executive directors, including Dr. Olivier Brandicourt and Ms. Shalini Sharp.